Hydromorphone controlled release

Drug Profile

Hydromorphone controlled release

Alternative Names: AP 77; Dilaudid; Dilaudid Oros; Exalgo; Hydromorphone extended release; Hydromorphone HCl; Hydromorphone hydrochloride; Jurnista; NMED-1077; OROS® Hydromorphone

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Therapeutic Discovery Corporation
  • Developer ALZA Corporation; Fresenius Kabi; Johnson & Johnson; Mallinckrodt Inc.
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer pain; Pain

Most Recent Events

  • 16 Feb 2017 Launched for Pain in USA (Parenteral) before February 2017
  • 11 Jun 2015 No recent reports of development identified - Phase-III for Cancer pain in Taiwan (PO)
  • 11 Jun 2015 No recent reports of development identified - Phase-III for Cancer pain in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top